Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198

Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program

Cantini, L., Belderbos, R. A., de Gooijer, C. J., Dumoulin, D. W., Cornelissen, R., Baart, S. J., Burgers, J. A., Baas, P., & Aerts, J. G. J. V. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-19-686 · Cited by 34

Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study

Rounis, K., Makrakis, D., Papadaki, C., Monastirioti, A. A., Vamvakas, L. N., Kalbakis, K., Gourlia, K., Xanthopoulos, I., Tsamardinos, I., Mavroudis, D., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252537 · Cited by 35

Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma

Aroldi, F., & Middleton, M. R. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00681-4 · Cited by 34

Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors

Wan, L., Wu, C., Luo, S., & Xie, X. (2022) · Disease Markers · doi:10.1155/2022/3610038 · Cited by 38

Multichannel Immune Nanoregulators Suppress Lactic Acid Metabolism and Lactic Acid‐Shaped Acidic Microenvironment to Uproot Anti‐Tumor Immunosuppression

Fang, C., Peng, Q., Li, X., Qu, X. D., Qiao, Z., Yin, B., Xiao, L., Chen, Y., Dong, X., Cai, L., et al. (2025) · Advanced Materials · doi:10.1002/adma.202512230 · Cited by 33

Role of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer

Park, S.-M., & Youn, J. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01165-6 · Cited by 33

Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases

Zhao, Q., Chen, Y., Du, S., Yang, X., Chen, Y., Ji, Y., & Zeng, Z. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1834792 · Cited by 33

Biomarkers related to immune checkpoint inhibitors therapy

Li, N., Hou, X., Huang, S., Tai, R., Lei, L., Li, S., Abuliz, A., Wang, G., & Yang, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112470 · Cited by 34

Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population–based analysis

Zhao, J., Li, D., Xie, S., Deng, X., Wen, X., Li, J., Wu, Z., Yang, X., Li, M., Tang, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1083840 · Cited by 33

Impact of Concomitant Medication Use and Immune-Related Adverse Events on Response to Immune Checkpoint Inhibitors

Gandhi, S., Pandey, M. R., Ammannagari, N., Wang, C., Bucsek, M. J., Hamad, L., Repasky, E. A., & Ernstoff, M. S. (2020) · Immunotherapy · doi:10.2217/imt-2019-0064 · Cited by 33

Targeting metabolic pathways to counter cancer immunotherapy resistance

Agarwala, Y., Brauns, T. A., Sluder, A. E., Poznansky, M. C., & Gemechu, Y. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.05.006 · Cited by 33

Predictive factors of response to immunotherapy—a review from the Spanish Melanoma Group (GEM)

On behalf of the Spanish Melanoma Group (GEM), Espinosa, E., Márquez‐Rodas, I., Soria, A., Berrocal, A., Manzano, J. L., González‐Cao, M., & Martín‐Algarra, S. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.08.10 · Cited by 33

Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies

Smoragiewicz, M., Bogaerts, J., Calvo, E., Marabelle, A., Perrone, A., Seymour, L., Shalabi, A., Siu, L. L., Tabernero, J. M., Giaccone, G., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy398 · Cited by 32

Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition

Knispel, S., Gassenmaier, M., Menzies, A. M., Loquai, C., Johnson, D. B., Franklin, C., Gutzmer, R., Hassel, J. C., Weishaupt, C., Eigentler, T., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.034 · Cited by 32

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors

de Glas, N. A., Bastiaannet, E., van den Bos, F., Mooijaart, S. P., van der Veldt, A. A. M., Suijkerbuijk, K. P. M., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Boers‐Sonderen, M. J., et al. (2021) · Cancers · doi:10.3390/cancers13112826 · Cited by 32

Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes

Schouwenburg, M. G., Jochems, A., Leeneman, B., Franken, M. G., van den Eertwegh, A. J. M., Haanen, J. B. A. G., van Zeijl, M. C. T., Aarts, M. J. B., van Akkooi, A. C. J., van den Berkmortel, F. W. P. J., et al. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000453 · Cited by 31

Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Zhang, Y., Liu, B., Kotenko, S. V., & Li, W. (2022) · Medicine · doi:10.1097/md.0000000000029536 · Cited by 31

Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse

Onesti, C. E., Josse, C., Boulet, D., Thiry, J., Beaumecker, B., Bours, V., & Jérusalem, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1761176 · Cited by 31

Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review)

You, W., Shang, B., Sun, J., Liu, X., Su, L., & Jiang, S. (2020) · Oncology Reports · doi:10.3892/or.2020.7643 · Cited by 31

Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It

Zielińska, M. K., Ciążyńska, M. A., Sulejczak, D., Rutkowski, P. L., & Czarnecka, A. M. (2025) · Biomolecules · doi:10.3390/biom15020269 · Cited by 30

Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma

Krückel, A., Moreira, A., Fröhlich, W., Schuler, G., & Heinzerling, L. (2019) · BMC Cancer · doi:10.1186/s12885-019-5384-z · Cited by 31

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer

Park, W., Mezquita, L., Okabe, N., Chae, Y. K., Kwon, D., Saravia, D., Auclin, É., Planchard, D., Caramella, C., Ferrara, R., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0643-y · Cited by 31

Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation–positive melanoma

Robert, C., Lewis, K. D., Gutzmer, R., Stroyakovskiy, D., Gogas, H. J., Анатольевна, П. С., Pereira, R. P., Eigentler, T., Rutkowski, P. L., Демидов, Л. В., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.01.076 · Cited by 32

Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study

Zheng, F., Meng, Q., Zhang, L., Chen, J., Zhao, L., Zhou, Z., & Liu, Y. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03077-8 · Cited by 30

Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study

Buonerba, C., Lorenzo, G. D., Pond, G. R., Cartenì, G., Scagliarini, S., Rozzi, A., Quevedo, F., Dorff, T. B., Nappi, L., Lanzetta, G., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00487 · Cited by 30

Refining PD-1/PD-L1 assessment for biomarker-guided immunotherapy: A review

Zdrenka, M., Kowalewski, A., Ahmadi, N., Sadiqi, R. U., Chmura, Ł., Borowczak, J., Maniewski, M., & Szylberg, Ł. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.9265 · Cited by 30

Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma

Jacquelot, N., Pitt, J. M., Enot, D. P., Roberti, M. P., Duong, C. P. M., Rusakiewicz, S., Eggermont, A. M. M., & Zitvogel, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1299303 · Cited by 29

Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?

Grob, J., Garbe, C., Ascierto, P. A., Larkin, J., Dummer, R., & Schadendorf, D. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30596-5 · Cited by 30

Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma

Keung, E. Z.-Y., & Gershenwald, J. E. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa012 · Cited by 29

Does Baking Soda Function as a Magic Bullet for Patients With Cancer? A Mini Review

Yang, M., Zhong, X., & Yuan, Y. (2020) · Integrative Cancer Therapies · doi:10.1177/1534735420922579 · Cited by 29

The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma

Fattore, L., Ruggiero, C. F., Liguoro, D., Castaldo, V., Catizone, A., Ciliberto, G., & Mancini, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.645069 · Cited by 31

Inflammation‐nutritional markers of peripheral blood could predict survival in advanced non‐small‐cell lung cancer patients treated with PD ‐1 inhibitors

Pu, D., Xu, Q., Zhou, L., Zhou, Y., Liu, J., & Ma, X. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14152 · Cited by 29

Deep Learning-Based Body Composition Analysis Predicts Outcome in Melanoma Patients Treated with Immune Checkpoint Inhibitors

Faron, A., Opheys, N. S., Nowak, S., Sprinkart, A. M., Isaak, A., Theis, M., Mesropyan, N., Endler, C., Sirokay, J. D., Pieper, C. C., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11122314 · Cited by 29

A small molecule inhibitor of VSIG-8 prevents its binding to VISTA

Chen, W., Qie, C., Hu, X., Wang, L., Jiang, J., Liu, W., & Liu, J. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01244-4 · Cited by 29

Prognostic and immune-related value of complement C1Q (C1QA, C1QB, and C1QC) in skin cutaneous melanoma

Yang, H., Che, D., Gu, Y., & Cao, D. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.940306 · Cited by 29

A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival

Keane, C., Tobin, J. W. D., Talaulikar, D., Green, M., Crooks, P., Jain, S., & Gandhi, M. K. (2018) · Oncotarget · doi:10.18632/oncotarget.25306 · Cited by 29

Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors

Zhu, Y., Zhao, F., Li, Z., & Yu, J. (2018) · Cancer Management and Research · doi:10.2147/cmar.s167400 · Cited by 29

Dissecting the Tumor–Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach

Chen, G. M., Azzam, A., Ding, Y., Barrett, D. M., Grupp, S. A., & Tan, K. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3888 · Cited by 28

The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis

Versluis, J. M., Hendriks, A. M., Weppler, A. M., Brown, L. J., de Joode, K., Suijkerbuijk, K. P. M., Zimmer, L., Kapiteijn, E., Allayous, C., Johnson, D. B., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.003 · Cited by 28

Human pluripotent stem cell-derived eosinophils reveal potent cytotoxicity against solid tumors

Lai, W., Xie, H., Liu, Y., Zheng, F., Zhang, Y., Lei, Q., Lv, L., Dong, J., Song, J., Gao, X. C., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.06.005 · Cited by 28

Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma

Rossi, N., Lee, K. A., Bermudez, M. V., Visconti, A., Thomas, A. M., Bolte, L. A., Björk, J. R., de Ruijter, L. K., Newton‐Bishop, J., Harland, M., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104235 · Cited by 29

PILE: a candidate prognostic score in cancer patients treated with immunotherapy

Güven, D. C., Yildirim, H. Ç., Bılgın, E., Aktepe, O. H., Taban, H., Şahin, T. K., Çakır, İ. Y., Akın, S., Dızdar, Ö., Aksoy, S., et al. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02560-6 · Cited by 28

Leucocyte and eosinophil counts predict progression‐free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD 1 inhibition

Hude, I., Sasse, S., Bröckelmann, P. J., von Tresckow, B., Momotow, J., Engert, A., & Borchmann, S. (2018) · British Journal of Haematology · doi:10.1111/bjh.14705 · Cited by 27

Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors

Fenton, S. E., Sosman, J. A., & Chandra, S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.28 · Cited by 28

Dual checkpoint inhibitor-associated eosinophilic enteritis

Yang, J., Lagana, S. M., Saenger, Y. M., & Carvajal, R. D. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0743-5 · Cited by 27

Primary malignant melanomas of the female lower genital tract: clinicopathological characteristics and management.

Wang, D., Xu, T., Zhu, H., Dong, J., & Fu, L. (2020) · PubMed Central · Cited by 27

Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1

Galland, L., Page, A. L. L., Lecuelle, J., Bibeau, F., Oulkhouir, Y., Dérangère, V., Truntzer, C., & Ghiringhelli, F. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1957603 · Cited by 27

Pretreatment eosinophil counts as a predictive biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors

Takeuchi, E., Kondo, K., Okano, Y., Ichihara, S., Kunishige, M., Kadota, N., Machida, H., Hatakeyama, N., Naruse, K., Ogino, H., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15100 · Cited by 27

Manipulation of Glucose Availability to Boost Cancer Immunotherapies

Marchesi, F., Vignali, D., Manini, B., Rigamonti, A., & Monti, P. (2020) · Cancers · doi:10.3390/cancers12102940 · Cited by 27

Surface-Enhanced Raman Spectroscopy for Cancer Immunotherapy Applications: Opportunities, Challenges, and Current Progress in Nanomaterial Strategies

Dey, S., Trau, M., & Koo, K. M. (2020) · Nanomaterials · doi:10.3390/nano10061145 · Cited by 26

Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment

Onesti, C. E., Josse, C., Poncin, A., Frères, P., Poulet, C., Bours, V., & Jérusalem, G. (2018) · Oncotarget · doi:10.18632/oncotarget.26120 · Cited by 26

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma

Krebs, F. K., Trzeciak, E. R., Zimmer, S., Özistanbullu, D., Mitzel-Rink, H., Meißner, M., Grabbe, S., Loquai, C., & Tuettenberg, A. (2021) · Cancer Medicine · doi:10.1002/cam4.3710 · Cited by 28

Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review

Baltussen, J. C., Welters, M. J. P., Verdegaal, E. M. E., Kapiteijn, E., Schrader, A. M. R., Slingerland, M., Liefers, G., van der Burg, S. H., Portielje, J. E. A., & de Glas, N. A. (2021) · Cancers · doi:10.3390/cancers13246366 · Cited by 28

Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights

Wang, X., Tian, H., Chi, Z., Si, L., Sheng, X., Hu, H., Gu, X., Li, S., Li, C., Lian, B., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010662 · Cited by 25

Tumor Metabolism as a Regulator of Tumor–Host Interactions in the B-Cell Lymphoma Microenvironment—Fueling Progression and Novel Brakes for Therapy

Beielstein, A. C., & Pallasch, C. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174158 · Cited by 26

Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer

Galland, L., Lecuelle, J., Favier, L., Fraisse, C., Lagrange, A., Kaderbhaï, C., Truntzer, C., & Ghiringhelli, F. (2021) · Cancers · doi:10.3390/cancers13123020 · Cited by 25

Inhibition of host Ogr1 enhances effector CD8+ T-cell function by modulating acidic microenvironment

Cao, L., Li, W., Yang, X., Zhang, W., Li, M., Zhang, H., Qin, C., Chen, X., & Gao, R. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00354-0 · Cited by 25

Development and Characterization of a Novel Non-Lytic Cancer Immunotherapy Using a Recombinant Arenavirus Vector Platform

Lauterbach, H., Schmidt, S., Katchar, K., Qing, X., Iacobucci, C., Hwang, A., Schlienger, K., Berka, U., Raguz, J., Ahmadi-Erber, S. M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.732166 · Cited by 27

Immunity and Breast Cancer: Focus on Eosinophils

Poncin, A., Onesti, C. E., Josse, C., Boulet, D., Thiry, J., Bours, V., & Jérusalem, G. (2021) · Biomedicines · doi:10.3390/biomedicines9091087 · Cited by 25

Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects

Pilla, L., Alberti, A., di Mauro, P., Gemelli, M. T., Cogliati, V., Cazzaniga, M. E., Bidoli, P., & Maccalli, C. (2020) · Cancers · doi:10.3390/cancers12113456 · Cited by 24

The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab

Furubayashi, N., Minato, A., Negishi, T., Sakamoto, N., Song, Y., Hori, Y., Tomoda, T., Tamura, S., Kuroiwa, K., Seki, N., et al. (2021) · Cancer Management and Research · doi:10.2147/cmar.s333823 · Cited by 24

Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy

Caliman, E., Fancelli, S., Ottanelli, C., Mazzoni, F., Paglialunga, L., Lavacchi, D., Michelet, M. R. G., Giommoni, E., Napolitano, B., Scolari, F., et al. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100603 · Cited by 24

Response of patients with melanoma to immune checkpoint blockade – insights gleaned from analysis of a new mathematical mechanistic model

Tsur, N., Kogan, Y., Rehm, M., & Agur, Z. (2019) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2019.110033 · Cited by 26

Factors related to rapid progression of non‐small cell lung cancer in Chinese patients treated using single‐agent immune checkpoint inhibitor treatment

Zhang, L., Bai, L., Liu, X., Liu, Y., Li, S., Liu, J., Zhang, S., Yang, C., Ren, X., & Cheng, Y. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13370 · Cited by 24

Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study

Herrmann, T., Ginzac, A., Molnar, I., Bailly, S., Durando, X., & Mahammedi, H. (2021) · Cancer Medicine · doi:10.1002/cam4.4208 · Cited by 25

Tebentafusp Induces a T-Cell–Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action

Hassel, J. C., Stanhope, S., Greenshields‐Watson, A., Machiraju, D., Enk, A. H., Holland, C., Abdullah, S. E., Benlahrech, A., Orloff, M. M., Nathan, P., et al. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.03.048 · Cited by 23

Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors

Mota, J. M., Teo, M. Y., Whiting, K. A., Li, H. A., Regazzi, A. M., Lee, C., Funt, S. A., Bajorin, D. F., Ostrovnaya, I., Iyer, G., et al. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000372 · Cited by 23

Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy

von Itzstein, M. S., Gonugunta, A. S., Sheffield, T. Y., Homsi, J., Dowell, J. E., Koh, A. Y., Raj, P., Fattah, F. J., Wang, Y., Basava, V. S., et al. (2022) · Cancers · doi:10.3390/cancers14051327 · Cited by 23

MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study

Salzmann, M., Pawlowski, J., Loquai, C., Rafei-Shamsabadi, D. A., Meiß, F., Ugurel, S., Schadendorf, D., Meier, F. E., Enk, A., & Hassel, J. C. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.02.008 · Cited by 23

Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma

Tomsitz, D., Schlaak, M. S., Zierold, S., Pesch, G., Schulz, T. U., Müller, G., Zecha, C., French, L. E., & Heinzerling, L. (2022) · Cancers · doi:10.3390/cancers14133282 · Cited by 23

Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab

Ikoma, T., Shimokawa, M., Matsumoto, T., Boku, S., Yasuda, T., Shibata, N., Kurioka, Y., Takatani, M., Nobuhisa, T., Namikawa, T., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03265-7 · Cited by 23

Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma

Ammann, N. L., Schwietzer, Y. F., Meß, C., Stadler, J.-C., Geidel, G., Kött, J., Pantel, K., Schneider, S. W., Utikal, J. S., Bauer, A. T., et al. (2022) · Cancers · doi:10.3390/cancers14225676 · Cited by 23

Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy

Zila, N., Eichhoff, O. M., Steiner, I., Mohr, T. T., Bileck, A., Cheng, P. F., Leitner, A., Gillet, L. C. J., Sajic, T., Goetze, S., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0562 · Cited by 23

Regulation of T cell antitumor immune response by tumor induced metabolic stress

Chalmin, F., Bruchard, M., Végran, F., & Ghiringhelli, F. (2019) · Cell Stress · doi:10.15698/cst2019.01.171 · Cited by 23

Hypereosinophilia in a Patient with Metastatic Non-Small-Cell Lung Cancer Treated with Antiprogrammed Cell Death 1 (anti-PD-1) Therapy

Lou, Y., Marin-Acevedo, J. A., Vishnu, P., Manochakian, R., Dholaria, B., Soyano, A. E., Luo, Y., Zhang, Y., & Knutson, K. L. (2019) · Immunotherapy · doi:10.2217/imt-2018-0128 · Cited by 23

Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials

Criscitiello, C., Marra, A., Morganti, S., Zagami, P., Viale, G., Espósito, A., & Curigliano, G. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0518 · Cited by 23

Exploring the Potential Use of a PBMC-Based Functional Assay to Identify Predictive Biomarkers for Anti-PD-1 Immunotherapy

Bacot, S. M., Harper, T. A., Matthews, R. L., Fennell, C. J., Akue, A. D., KuKuruga, M. A., Lee, S., Wang, T., & Feldman, G. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239023 · Cited by 23

Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial

Ascierto, P. A., Vanella, V., Grimaldi, A. M., Festino, L., Palla, M., Simeone, E., & Mozzillo, N. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1898-2 · Cited by 22

Predictive biomarkers for tumor immune checkpoint blockade

Tong, M., Wang, J., He, W., Wang, Y., Pan, H., Li, D., & Zhang, H. (2018) · Cancer Management and Research · doi:10.2147/cmar.s179680 · Cited by 22

Eosinophils and melanoma: Implications for immunotherapy

Robinson, I., Lucia, G. S., Li, A. R., Oberholtzer, N. P., Plante, J. G., Quinn, K. M., Reuben, D. Y., Mehrotra, S., & Valdebran, M. (2021) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13025 · Cited by 23

Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study

Cheng, Y., Chen, D.-W., Chen, P., He, X., Li, P., Lin, Z.-S., Chen, S., Ye, S., & Lan, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.809971 · Cited by 22

Inflammatory Biomarkers in Assessing Severity and Prognosis of Immune Checkpoint Inhibitor-Associated Cardiotoxicity

Liang, L., Cui, C., Lv, D., Li, Y., Huang, L., Feng, J., An, T., Tian, P., Yang, K. G., Hu, L., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14340 · Cited by 22

New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review)

Wang, Y., Yang, S., Wan, L., Ling, W., Chen, H. H., & Wang, J. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5534 · Cited by 22

Association of the CD4+/CD8+ ratio with response to PD-1 inhibitor-based combination therapy and dermatological toxicities in patients with advanced gastric and esophageal cancer

Xu, S., Zhu, Q., Wu, L., Wang, Y., Wang, J., Zhu, L., Zheng, S., Hang, J., & Hang, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110642 · Cited by 22

Early Change in Peripheral CD4 + T Cells Associated with Clinical Outcomes of Immunotherapy in Gastrointestinal Cancer

Liu, C. X., Wang, Y., Li, S., Jiao, X., Zou, J., Wang, Z., Qi, C., Zhang, X., Li, J., Lü, Z., et al. (2020) · Immunotherapy · doi:10.2217/imt-2020-0068 · Cited by 22

Predictive Biomarkers for PD-1 and PD-L1 Immune Checkpoint Blockade Therapy

Song, Y., Li, Z., Xue, W., & Zhang, M. (2019) · Immunotherapy · doi:10.2217/imt-2018-0173 · Cited by 21

Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy

Tomela, K., Pietrzak, B., Galus, Ł., Mackiewicz, J., SCHMIDT, M. T., Mackiewicz, A. A., & Kaczmarek, M. (2023) · Cells · doi:10.3390/cells12050789 · Cited by 23

Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016

Ascierto, P. A., Agarwala, S. S., Ciliberto, G., Demaria, S., Dummer, R., Duong, C. P. M., Ferrone, S., Formenti, S. C., Garbe, C., Halaban, R., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1341-2 · Cited by 23

Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma

Hu, J., Ravichandran, S., Rushing, C. N., Beasley, G. M., Hanks, B. A., Jung, S., Salama, A. K. S., Ho, L. M., & Mosca, P. J. (2020) · Anticancer Research · doi:10.21873/anticanres.14528 · Cited by 21

The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients

Tomela, K., Pietrzak, B., SCHMIDT, M. T., & Mackiewicz, A. A. (2020) · Life · doi:10.3390/life10100219 · Cited by 21

Prognostic value of 2-[18F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy

Schweighofer-Zwink, G., Manafi‐Farid, R., Kölblinger, P., Hehenwarter, L., Harsini, S., Pirich, C., & Beheshti, M. (2021) · European Journal of Radiology · doi:10.1016/j.ejrad.2021.110107 · Cited by 21

Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer

Hurkmans, D. P., Verdegaal, E. M. E., Hogan, S. A., de Wijn, R., Hovestad, L., van den Heuvel, D. M. A., Ruijtenbeek, R., Welters, M. J. P., van Brakel, M., Basak, E. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001607 · Cited by 20

Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein

Buschow, S. I., Ramazzotti, M., Reinieren-Beeren, I., Heinzerling, L., Westdorp, H., Stefanini, I., Beltrame, L., Hato, S. V., Ellebæk, E., Groß, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18698 · Cited by 20

Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint Inhibitors

Afzal, M. Z., Sarwar, T., & Shirai, K. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000272 · Cited by 20

Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma

Rizk, E. M., Seffens, A., Trager, M. H., Moore, M. R., Geskin, L. J., Gartrell, R. D., Wong, W., & Saenger, Y. M. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00475-1 · Cited by 21

Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response

Navani, V., Graves, M. C., Bowden, N. A., & van der Westhuizen, A. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14352 · Cited by 20

Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma

Orsi, G., Tovoli, F., Dadduzio, V., Vivaldi, C., Brunetti, O., Ielasi, L., Conti, F., Rovesti, G., Gramantieri, L., Rizzato, M. D., et al. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00757-3 · Cited by 20

Lower risk of severe checkpoint inhibitor toxicity in more advanced disease

Verheijden, R. J., May, A. M., Blank, C. U., van der Veldt, A. A. M., Boers‐Sonderen, M. J., Aarts, M. J. B., van den Berkmortel, F. W. P. J., van den Eertwegh, A. J. M., de Groot, J. W. B., van der Hoeven, J. J. M., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000945 · Cited by 20

Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors

Hurkmans, D. P., Sassen, S. D. T., de Joode, K., Putter, L., Basak, E. A., Wijkhuijs, A. J. M., Joerger, M., Debets, R., Koch, B. C. P., van der Leest, C. H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002344 · Cited by 20

Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma

Loo, K. L., Smithy, J. W., Postow, M. A., & Warner, A. B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.810388 · Cited by 23

Baseline biomarkers correlated with outcome in advanced melanoma treated with pembrolizumab monotherapy.

Awada, G., Schwarze, J. K., Gondry, O., Jansen, Y. J. L., Ong, S., Gorman, K. M., Warren, S. E., Kockx, M. M., Seremet, T., Keyaerts, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.e22041 · Cited by 3

A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab

Awada, G., Jansen, Y. J. L., Schwarze, J. K., Tijtgat, J., Hellinckx, L., Gondry, O., Vermeulen, S., Warren, S. E., Schats, K., van Dam, P., et al. (2021) · Cancers · doi:10.3390/cancers13020168 · Cited by 36

Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma

Ferrucci, P. F., Gandini, S., Cocorocchio, E., Pala, L., Baldini, F., Mosconi, M., Cappellini, G. C. A., Albertazzi, E., & Martinoli, C. (2017) · Oncotarget · doi:10.18632/oncotarget.19748 · Cited by 41

Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients

Failing, J. J., Yan, Y., Porrata, L. F., & Markovic, S. N. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000404 · Cited by 44

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Martens, A., Wistuba-Hamprecht, K., Foppen, M. G., Yuan, J., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2412 · Cited by 541